PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :		(11) International Publication Number:
A61K 9/72	A1	WO 92/18110
		(43) International Publication Date: 29 October 1992 (29.10.92)

(21) International Application Number: PCT/SE92/00186

(22) International Filing Date: 24 March 1992 (24.03.92)

(30) Priority data:
9101090-0 11 April 1991 (11.04.91) SE

(71) Applicant *(for all designated States except US):* AKTIEBOLAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only) :* TROFAST, Jan [SE/SE]; TROFAST, Eva [SE/SE]; Vapenkroken 34, S-224 47 Lund (SE). BYSTRÖM, Katarina [SE/SE]; Stora Vänern, Kullavägen, S-240 13 Genarp (SE). JAKUPOVIC, Edib [YU/SE]; Smultronvägen 7, S-155 00 Nykvarn (SE).

(74) Agents: DANIELSSON, Sten et al.; AB Astra, Patent Department, S-151 85 Södertälje (SE).

(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.

Published
With international search report.

(54) Title: PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES

(57) Abstract

A process for providing water-soluble micronized substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such substances, which process is carried out by: a) reducing, if necessary, the residual water from the micronized substance by drying optionally at an elevated temperature and/or vacuum; b) conditioning said dried, micronized substances with a solvent; and c) eliminating residual solvent by storing in a dry place like vacuum or by purging with an inert gas.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CS	Czechoslovakia
DE	Germany
DK	Denmark
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GN	Guinea
GR	Greece
HU	Hungary
IT	Italy
JP	Japan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
LI	Liechtenstein
LK	Sri Lanka
LU	Luxembourg
MC	Monaco
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
NL	Netherlands
NO	Norway
PL	Poland
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SN	Senegal
SU	Soviet Union
TD	Chad
TG	Togo
US	United States of America

PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES

Field of the invention

The present invention relates to a process for providing water-soluble micronized substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such substances and which have improved physicochemical properties in the dry state, thereby facilitating the technical handling and significantly increasing the medical value of the substances.

Background of the invention

During the past few years, there have been frequent demonstrations of the fact that the appropriate selection of the most suitable crystalline modification significantly can influence the clinical results of a given chemical entity. The chemical and physical stability of a solid compound in a particular dosage form can be modified by presenting the substance in the appropriate crystal form. Little information is available on the role of polymorphism and crystal habit in solid dosage form and powder technology. It is, however, apparent that the appropriate selection of the most suitable crystalline modification, whether arising from polymorphic differences or as a result of solvate complex formation of both water-soluble substances and less water-soluble substances, such as theophylline, often significantly can increase the medical value of a given drug in a particular dosage form. There are only a few statements available to predict the outcome of a crystallization procedure if e.g. the substance could be involved in different polymorphic or pseudopolymorphic forms. Solid-state transformations may also occur during mechanical treatment, e.g. micronization and by pressure during tableting. While a few generalizations can be made concerning the influence of structural modifications on

the tendency of a chosen compound to exhibit polymorphism or other phenomena, a complete understanding of this problem awaits further research. Often "trial and error" approaches are used to develop a successful formulation of a drug. It is necessary to establish the conditions whereby different forms of a substance might be converted to a single form thus eliminating differences in solid-state properties and subsequent different physico-chemical properties.

E. Shefter and T. Higuchi have measured the relative rates of dissolution of several crystalline solvated and non-solvated forms of important pharmaceuticals, J. Pharm. Sci., 52 (8), (1963), 781-91.

L. van Campen, G. Zografi and J.T. Carstensen give in a review article an approach to the evaluation of hygroscopicity for pharmaceutical solids, Int. J. Pharmceut. 5, (1980), 1-18.

C. Ahlneck and G. Zografi describe the molecular basis of moisture on the physical and chemical stability of drugs in the solid state, Int. J. Pharmceut., 62, (1990), 87-95.

M. Otsuka et al. have calculated hydration data using various solid-state kinetic models for theophylline anhydrate powder, J. Pharm. Pharmacol., 42, (1990), 606-610.

Hak-Kim Chan and Igor Gonda have examined the properties of respirable crystals of cromoglycic acid by using different methods, J. Pharm. Sci., 78 (2), (1989), 176-80.

A more comprehensive discussion of factors relating to pharmaceutical preformulations and the physicochemical properties of drug substances is given by J.I. Wells in Pharmaceutical Preformulation: The Physicochemical

Properties of Drug Substances, John Wiley & Sons, New York (1988). See particularly the chapter about polymorphism pp 86-91.

Brief description of the invention

The object of the invention is to provide a process for water-soluble micronized substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such substances, whereby reducing the residual water from the micronized substances, conditioning said dried, micronized substances with a solvent and finally eliminating residual solvent from the substances.

Detailed description of the invention

The object of the present invention is to provide a reliable process, where the desired polymorphic form can be conveniently and reproducibly prepared. The invention relates to a three step procedure:

a. reducing, if necessary, the residual water from the micronized substance by drying optionally at an elevated temperature and/or vacuum.
b. conditioning said dried micronized substance with a solvent, and
c. eliminating the residual solvent by storing the substance in a dry place, such as vacuum, or by purging with an inert gas.

The solvents used in the conditioning step b) are organic alcohols, ketones, esters, acetonitrile and the like, most preferably lower alcohols like methanol, ethanol, n-propanol, isopropanol; lower ketones like acetone, methylethylketone; ethylacetate, preferably in the vapour phase.

According to one preferred embodiment the conditioning step b) is carried out in an inert gas containing solvent vapour.

The inert gas used in step c) and optionally in step b) is preferably nitrogen.

The preferred substances on which the invention is to be applied are carbohydrates, amino acids and drugs.

Carbohydrates, such as lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, xylitol, mannitol, myoinositol and the like, and amino acids, such as alanine, betaine and the like, are often used as additives in pharmaceutical compositions e.g. as additives in certain inhalation formulations.

Terbutaline sulfate, salbutamol sulfate, fenoterol hydrobromide and bambuterol hydrochloride are highly selective β_2-adrenergic agonist having bronchospasmolytic effect and are effective in the treatment of reversible obstructive lung ailments of various genesis, particularly asthmatic conditions. Disodium chromoglycate (DSCG) has been used as a prophylactic agent in the treatment of allergic bronchial asthma for many years.

The invention will be described by using lactose, terbutaline sulfate and salbutamol sulfate as examples. The phenomena of solvate formation and polymorphism are well recognized in the literature in the preformulation studies in the development phase for new drugs in the solid state. e.g. the US Pharmacopoeia recognizes >90 drug hydrates!

Many substances exist in different polymorphs (pseudopolymorphs) and several metastabile solvates with variable composition and physical properties like bulk density and

hygroscopicity. Several transformations between these polymorphs may occur at different velocity. These effects are operating when crystalline substances have been activated by various processes such as grinding, freeze drying, micronization or recrystallization to produce regions of partial amorphous structure. The substances often will be obtained in an amorphous state or a metastable crystalline form when spray drying, freeze drying, rapid solvent quenching or when using controlled precipitation where both crystalline and amorphous forms can be prepared. The use of an amorphous form or a metastable crystalline form is often limited due to its thermodynamic instability. It is therefore a desire to convert the amorphous form or the metastable crystalline formto the more stable crystalline state. The present invention deals with such physical and chemical changes, or more importantly, to anticipate them and the means by which these solid-state phenomena can be handled.

After recrystallization (or after spray drying/freeze-drying) the substance has to be micronized to the final particle size required for e.g. inhalation. The particles should be less than 100 µm and preferably less than 10 µm. For crystalline substances, the micronization step seems to give an amorphous outer layer of the particle making the particle more sensitive to moisture.

It is an object of this invention to be able to reliably provide a crystalline form of certain water-soluble substances, which can be produced, stored and used, while maintaining the aerodynamic properties and specifications (particle size, particle form, hygroscopicity etc) required for inhalation of such substances. The particle size of the micronized substances is identical before and after the conditioning step as measured by different instruments like Malvern Master Sizer, culter counter or a microscope.

The conditioning of the substance probably rearrange the

outer layer of the crystals or the amorphous substance giving a more stable and less hygroscopic product.

In some instances it has been possible to use infrared spectroscopy in order to study the conversion of an amorphous form or a partly crystalline form into a stable crystalline form. Other methods available include BET gas adsorption, X-ray powder diffraction, microcalorimetry and differential scanning calorimetry (DSC). We have found that BET gas adsorption and microcalorimetry being the best methods for distinguishing the different forms of the tested compounds.

Test results

The surface area measured by determining the quantity of a gas (nitrogen) that adsorbs as a single layer of molecules, a monomolecular layer on a sample is formed (Flowsorb II 2300, Micromeritics Co, USA). Surface area after the sample has been standing in high humidity for 24 hrs.

Micronized substance (m^2/g)	Non-conditioned substance (m^2/g)	Conditioned substance (m^2/g)
Terbutaline sulfate:		
11 - 12.5	< 3	7 - 9
Salbutamol sulfate:		
8.4	3	5.9

With the low surface area, obtained when micronized substance has been stored at high humidity, the bulk substance has a great tendency to aggregate when stored, which make the substance very difficult for technical handling in

manufacturing the different formulations needed.

The interactions between certain substances and water vapour have also been studied by microcalorimetry. When said substances are subjected to water in the vapour phase they give off heat in a highly cooperative process. This moisture induced phase transition is however not observed for the conditioned substance. Thus, the conditioning process transforms the substance into a more stable form that is less sensitive to humidity.

Comparison of the heat given off by non-conditioned and conditioned substances when subjected to water vapour. Experiments are performed by a Thermal Activity Monitor 2277 (Thermometrics, Sweden).

	Heat (J/g)	
Relative humidity (%)	Non-conditioned substance	Conditioned substance
Terbutaline sulfate		
58	3.6	0.1
75	6.2	0.1
Salbutamol sulfate		
75	6 - 8	0.1

When spray-dried lactose has been conditioned in ethanol vapour for 100 hours at room temperature the energy given off was < 0.1 J/g, while the unconditioned lactose loses 40-44 J/g when subjected to water vapour.

The stability of the particles being conditioned were astonishing and will in a remarkable way increase the flexibility of the use of the substance for different formulations.

Experimental procedure

The invention is further illustrated but not limited by the following example.

Example 1

3.6 kg terbutaline sulphate micronized was dried in a stainless steel column with 200 mm diameter at 90°C in vacuum for 23 hours. The dried substance was cooled to about 30°C and the pressure was normalized with ethanol-saturated nitrogen gas. 70 ml/min of ethanol-saturated nitrogen gas was then passed through the 200 mm diameter column for 60 hours to condition the substance. During this time the column was inverted a few times. The residual solvent was eliminated by purging with nitrogen gas for 2 hours and the product, about 3.5 kg, was packed in double plastic bags with a drying agent between the bags.

Example 2

In one experiment 1 g micronized salbutamol sulfate was kept at room temperature for 24 hours in a closed vessel containing a beaker filled with ethanol. The sample was removed and stored in a completely dry environment over night in order to eliminate traces of ethanol. The sample was subjected for analysis (see test results given above).

It is necessary to introduce stirring or tumbling of the substance when conditioning in larger scale.

Example 3

1 g spray-dried amorphous lactose was treated as in exemple 2. The time kept in the saturated ethanol vapour was 100 hours. After removal of residual ethanol, the sample was subjected for calorimetric analysis (see test results given above).

CLAIMS

1. A process for providing water-soluble micronized substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such substances, c h a r a c t e r i z e d in
a) reducing, if necessary, the residual water from the micronized substance by drying optionally at an elevated temperature and/or vacuum,
b) conditioning said dried, micronized substances with a solvent, and
c) eliminating residual solvent by storing in a dry place like vacuum or by purging with an inert gas.

2. A process according to claim 1, c h a r a c t e r i z e d in that the solvent used in the conditioning step b) is ethanol, acetone or the like, preferably in the vapour phase.

3. A process according to claim 2, c h a r a c t e r i z e d in that the solvent used in step b) is ethanol.

4. A process according to any one of claims 1-3, c h a r a c t e r i z e d in that the conditioning step b) is carried out in an inert gas containing solvent vapour.

5. A process according to any one of claims 1-4, c h a r a c t e r i z e d in that the inert gas used in step c) and optionally in step b) is nitrogen.

6. A process according to any one of claims 1-5, c h a r a c t e r i z e d in that the substances are additives, such as carbohydrates and amino acids.

7. A process according to claim 6, c h a r a c t e r i z e d in that the carbohydrates used are lactose,

glucose, fructose, galactose, trehalose, sucrose, maltose, xylitol, mannitol, myoinositol or the like and the amino acids used are alanine, betaine or the like.

8. A process according to any one of claims 1-6, c h a r a c t e r i z e d in that the substances are drugs.

9. A process according to claim 8, c h a r a c t e - r i z e d in that said drugs are antiasthmatic or antiallergic substances.

10. A process according to claim 8, c h a r a c t e - r i z e d in that said antiasthmatic or antiallergic substances are selected from terbutaline sulfate, salbutamol sulfate, fenoterol hydrobromide, bambuterol hydrochloride, terfenadine and disodium chromoglycate.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 92/00186

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5: A 61 K 9/72

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
IPC5	A 61 K

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched[8]

SE,DK,FI,NO classes as above

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category *	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
A	EP, A1, 0436110 (BIOCHEMIE GESELLSCHAFT M.B.H.) 10 July 1991, page 3, line 17 - line 54 --	1-10
A	US, A, 4405598 (BROWN K ET AL.) 20 September 1983, col. 4, line 4 - line 27 --	1-10
A	WO, A1, 8607547 (GERGELY G. ET AL) 31 December 1986, see the whole document --	1-10

---

* Special categories of cited documents:[10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
16th July 1992	1992 -07- 21
International Searching Authority	Signature of Authorized Officer
SWEDISH PATENT OFFICE	Anneli Jönsson

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 92/00186

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 29/05/92 The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A1- 0436110	91-07-10	AU-D-	6870191	91-06-26
		CA-A-	2030581	91-05-25
		JP-A-	3172181	91-07-25
		WO-A-	91/07948	91-06-13
US-A- 4405598	83-09-20	CA-A-	1120401	82-03-23
		AU-B-	512593	80-10-16
		AU-D-	2162677	78-08-03
		BE-A-	850727	77-07-25
		CA-A-	1176171	84-10-16
		DE-A-C-	2703119	77-08-04
		FR-A-B-	2339604	77-08-26
		GB-A-	1562901	80-03-19
		JP-C-	1366290	87-02-26
		JP-A-	52094411	77-08-09
		JP-B-	61029929	86-07-10
		LU-A-	76661	77-08-03
		NL-A-	7700911	77-08-02
		SE-B-C-	442267	85-12-16
		SE-B-C-	442268	85-12-16
		SE-A-	7700888	77-07-31
		SE-A-	8107278	81-12-04
		AU-B-	522792	82-06-24
		AU-D-	3805778	80-01-17
		BE-A-	869055	79-01-17
		CA-A-	1112567	81-11-17
		CH-A-	627075	81-12-31
		DE-A-C-	2831419	79-02-01
		FR-A-B-	2397833	79-02-16
		GB-A-B-	2001334	79-01-31
		JP-B-	1011615	89-02-27
		JP-C-	1532970	89-11-24
		JP-A-	54035209	79-03-15
		NL-A-	7807625	79-01-23
		SE-B-C-	443087	86-02-17
		SE-A-	7807934	79-01-20
WO-A1- 8607547	86-12-31	EP-A-B-	0258258	88-03-09
		JP-T-	63501137	88-04-28
		US-A-	4876802	89-10-31
		US-A-	4911930	90-03-27